1 week Ago By ABMN Staff
Private Advisor Group LLC cut its holdings in Novo Nordisk A/S ( NYSE:NVO – Free Report ) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 94,137 shares of the company’s stock after selling 894 shares during the period.
Private Advisor Group LLC’s holdings in Novo Nordisk A/S were worth $13,437,000 at the end of the most recent reporting period. Several other hedge funds have also added to or reduced their stakes in NVO. Aveo Capital Partners LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $205,000.
9258 Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 4.0% during the fourth quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock valued at $260,000 after acquiring an additional 97 shares during the last quarter.
Rollins Financial raised its stake in shares of Novo Nordisk A/S by 10.4% during the fourth quarter. Rollins Financial now owns 3,894 shares of the company’s stock valued at $403,000 after acquiring an additional 368 shares during the last quarter.
Charles Schwab Investment Management Inc. raised its stake in shares of Novo Nordisk A/S by 38.1% during the fourth quarter.
Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after acquiring an additional 26,067 shares during the last quarter. Finally, Gryphon Financial Partners LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $237,000.
11.54% of the stock is owned by institutional investors. Analyst Ratings Changes Several equities analysts have recently commented on NVO shares.
StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th.
They set a “buy” rating and a $156.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.
00 price objective on shares of Novo Nordisk A/S in a research note on Monday, August 19th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $170.00 to $160.
00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Argus boosted their price target on shares of Novo Nordisk A/S from $125.00 to $160.
00 and gave the company a “buy” rating in a research report on Monday, June 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.
com, the company has an average rating of “Moderate Buy” and a consensus price target of $145.17. Novo Nordisk A/S Price Performance Shares of NYSE NVO opened at $131.
14 on Friday. Novo Nordisk A/S has a 1 year low of $86.96 and a 1 year high of $148.
15. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.
94 and a quick ratio of 0.75. The company’s 50-day moving average is $134.
79 and its 200 day moving average is $132.55. The stock has a market capitalization of $588.
49 billion, a P/E ratio of 45.22, a P/E/G ratio of 1.52 and a beta of 0.
42. Novo Nordisk A/S ( NYSE:NVO – Get Free Report ) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.
65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06).
The business had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion.
Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%.
On average, sell-side analysts expect that Novo Nordisk A/S will post 3.11 earnings per share for the current year. Novo Nordisk A/S Cuts Dividend The firm also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th.
Shareholders of record on Friday, August 16th were issued a $0.5126 dividend. This represents a yield of 0.
7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.
83%. Novo Nordisk A/S Profile ( Free Report ) Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S ( NYSE:NVO – Free Report ). Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.
com's FREE daily email newsletter ..
